-+ 0.00%
-+ 0.00%
-+ 0.00%

Emmaus Life Sciences delays Q3 report to complete convertible note valuation

PUBT·11/16/2026 20:25:03
Emmaus Life Sciences delays Q3 report to complete convertible note valuation
  • Emmaus Life Sciences expects to file its delayed September 30, 2026, Form 10-Q within five calendar days of the prescribed deadline.
  • The delay reflects additional time needed to value the conversion feature of outstanding convertible promissory notes.
  • Net revenue is expected to fall more than 40% following completion of the U.S. Endari out-license to NeoImmuneTech during the quarter.
  • An operating loss of approximately $400,000 is expected, compared with operating income of approximately $700,000 a year earlier.
  • Estimated net loss widened to approximately $0.06 per share from $0.03 a year earlier, subject to the final conversion-feature valuation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-120539), on November 16, 2026, and is solely responsible for the information contained therein.